secwatch.observer — SEC 8-K summary
======================================

Issuer:     FENNEC PHARMACEUTICALS INC. (FENC)
CIK:        0001211583
Form:       8-K
Filed at:   2024-02-29T23:59:59+00:00
Accession:  0001104659-24-029355
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fennec prelim Q4 2023 net revenue $9.2-9.7M (+41-49% QoQ); FY 2023 $20.7-21.2M
------------------------------------------------------------------------------

- Q4 2023 net revenue expected $9.2-9.7M, up 41-49% from Q3 2023.
- Full-year 2023 net revenue expected $20.7-21.2M.
- Audited Q4 and full-year results expected on or about March 26, 2024.
- PEDMARK is first FDA-approved therapy to reduce ototoxicity risk in pediatric cisplatin patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1211583/000110465924029355/0001104659-24-029355-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1211583/000110465924029355/tm247601d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-029355

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer